Pharmacokinetics and safety of the monoclonal antibody tobevibart (VIR-3434) administered as monotherapy or in combination with the small interfering RNA elebsiran (VIR-2218) in cirrhotic participants with mild hepatic impairment

被引：0
|
作者：
Wang, Li [1 ]
Gupta, Sneha [1 ]
Chattergoon, Michael A. [1 ]
El-Zailik, Asma [1 ]
Huang, Cheng [1 ]
Hristopoulos, George [1 ]
Reyes, Maribel [1 ]
机构：
[1] Vir Biotechnol Inc, San Francisco, CA USA
来源：
JOURNAL OF HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
WED-389
引用
收藏
页码：S816 / S816
页数：1
相关论文
共 7 条
  • [1] SAFETY PROFILE OF TOBEVIBART ( VIR-3434) AND ELEBSIRAN ( VIR-2218) FOR THE TREATMENT OF CHRONIC HEPATITIS B AND DELTA ( CHB AND CHD)
    Jucov, Alina
    Gane, Edward
    Yuen, Man-Fung
    Agarwal, Kosh
    Streinu-Cercel, Anca
    Lim, Young-Suk
    Boundy, Keith
    Pilowa, Cara
    Chattergoon, Michael
    Arizpe, Andre
    Thanawala, Vaidehi
    Yu, Shuli
    Wu, Pan
    Lu, Yimeng
    Correll, Todd
    Asselah, Tarik
    HEPATOLOGY, 2024, 80 : S300 - S301
  • [2] PHARMACOKINETICS AND SAFETY OF VIR-2218 MONOTHERAPY IN ADULT CIRRHOTIC PARTICIPANTS WITH MODERATE HEPATIC IMPAIRMENT
    Wang, Li
    Chattergoon, Michael A.
    Elie, Sophia
    Wu, Pan
    Hristopoulos, George
    Gupta, Sneha
    Reyes, Maribel
    HEPATOLOGY, 2023, 78 : S581 - S582
  • [3] Efficacy and safety of tobevibart (VIR-3434) alone or in combination with elebsiran (VIR-2218) in participants with chronic hepatitis delta virus infection: preliminary results from the phase 2 SOLSTICE trial in non-cirrhotic and compensated cirrhotic participants
    Asselah, Tarik
    Streinu-Cercel, Anca
    Jucov, Alina
    Gane, Edward J.
    Wedemeyer, Heiner
    Lampertico, Pietro
    Chattergoon, Michael A.
    Wu, Pan
    Maciejewski, Sonia
    Pilowa, Cara
    Hassani, Afshar
    Correll, Todd
    Hwang, Carey
    Agarwal, Kosh
    JOURNAL OF HEPATOLOGY, 2024, 80 : S75 - S76
  • [4] EFFICACY AND SAFETY OF TOBEVIBART (VIR-3434) ALONE OR IN COMBINATION WITH ELEBSIRAN (VIR-2218) IN PARTICIPANTS WITH CHRONIC HEPATITIS DELTA VIRUS INFECTION: WEEK 24 PRIMARY ENDPOINT ANALYSIS FROM THE PHASE 2 SOLSTICE TRIAL
    Asselah, Tarik
    Streinu-Cercel, Anca
    Jucov, Alina
    Gane, Edward
    Wedemeyer, Heiner
    Lampertico, Pietro
    Chattergoon, Michael
    Chow, Sophia
    Wu, Pan
    Pilowa, Cara
    Correll, Todd
    Hwang, Carey
    Agarwal, Kosh
    HEPATOLOGY, 2024, 80 : S1987 - S1988
  • [5] PHARMACOKINETICS AND SAFETY OF A SINGLE DOSE OF ELEBSIRAN ( VIR-2218, SIRNA) SUBCUTANEOUSLY ADMINISTERED IN ADULT PARTICIPANTS WITH MODERATE RENAL IMPAIRMENT
    Wang, Li
    El-zailik, Asma
    Boundy, Keith
    Mao, Shenghua
    Aryal, Madhukar
    Gupta, Sneha
    Reyes, Maribel
    HEPATOLOGY, 2024, 80 : S268 - S269
  • [6] SAFETY, TOLERABILITY, AND ANTIVIRAL ACTIVITY OF THE siRNA VIR-2218 IN COMBINATION WITH THE INVESTIGATIONAL NEUTRALIZING MONOCLONAL ANTIBODY VIR-3434 FOR THE TREATMENT OF CHRONIC HEPATITIS B VIRUS INFECTION: PRELIMINARY RESULTS FROM THE PHASE 2 MARCH TRIAL
    Gane, Edward
    Jucov, Alina
    Dobryanska, Marta
    Yoon, Ki Tae
    Lim, Tien Huey
    Arizpe, Andre
    Cloutier, Daniel
    Shen, Ling
    Gupta, Sneha V.
    Lau, Audrey H.
    Hwang, Carey
    Lim, Young-Suk
    HEPATOLOGY, 2022, 76 : S18 - S19
  • [7] Safetyand antiviral activity of short-duration combinations of the investigational small interfering ribonucleic acid VIR-2218 with the neutralizing, vaccinal monoclonal antibody VIR-3434: post-treatment follow-up from the Phase 2 MARCH trial
    Gane, Edward J.
    Jucov, Alina
    Dobryanksa, Marta
    Yoon, Ki Tae
    Lim, Tien Huey
    Arizpe, Andre
    Cloutier, Daniel
    Chattergoon, Michael
    Mao, Shenghua
    Gupta, Sneha V.
    Camus, Gregory
    Hwang, Carey
    Lim, Young-Suk
    JOURNAL OF HEPATOLOGY, 2023, 78 : S34 - S35
1